Tdspharm Co., Ltd.

464280 · KQ · Healthcare / Drug Manufacturers - General

4,120.00KRW-60.00 (-1.44%)

Price History

Full chart

Market Stats

Previous Close4,180.00

Open4,185.00

Day Range4,020.00 – 4,305.00

52-Week Range4,240.00 – 10,800.00

Volume8.84K

Market Cap28.51B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta0.35

50-Day Avg5,588.70

200-Day Avg7,715.53

About

Tdspharm Co., Ltd. researches, develops, and produces pharmaceuticals and cosmetics in South Korea and internationally. It offers general medicines, prescription drugs, and non-medicinal products. The company was founded in 2002 and is based in Seongnam-si, South Korea.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - General
CEOCheoljun Kim
Employees0
HeadquartersC-403 ,253, Pangyo-ro, Seongnam-si, South Korea, 13486, Korea
Websitehttps://www.tdspharm.com

Leadership

Cheoljun KimCEO & Inside Director · b. 1968
DongYeol ShinChief Financial Officer · b. 1981
Young Moo LeeDirector of Research Institute & Executive Director · b. 1965

Financials

Income Statement

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	19.82B	25.59B	30.05B	27.52B	27.62B
Growth (%)	-	+29.11%	+17.43%	-8.42%	+0.37%
Cost of Revenue	15.83B	19.42B	22.11B	19.80B	20.12B
Gross Profit	3.99B	6.17B	7.94B	7.72B	7.50B
Gross Margin	20.11%	24.10%	26.43%	28.06%	27.17%
Operating Expense	1.67B	2.44B	2.92B	3.99B	3.74B
Operating Income	2.31B	3.73B	5.02B	3.73B	3.77B
Operating Margin	11.68%	14.57%	16.69%	13.55%	13.63%
EBITDA	-	5.33B	6.81B	5.15B	5.90B
EBITDA Margin	-	20.84%	22.67%	18.71%	21.34%
Net Income	2.06B	3.46B	4.69B	3.72B	4.27B
Net Income Margin	10.41%	13.50%	15.60%	13.51%	15.48%
R&D	356.11M	478.84M	441.20M	622.50M	665.91M
R&D as % of Total Revenue	1.80%	1.87%	1.47%	2.26%	2.41%
Interest Expense	129.58M	220.65M	301.46M	267.69M	222.78M
Interest Expense % of Total Revenue	0.65%	0.86%	1.00%	0.97%	0.81%

Balance Sheet

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	26.97B	30.47B	33.97B	49.16B	54.15B
Total Liabilities	10.82B	12.16B	11.03B	10.66B	11.37B
Total Equity	16.14B	18.31B	22.94B	38.50B	42.78B
Cash	1.62B	3.28M	1.64B	4.70B	1.21B
Net Debt	5.38B	3.74B	5.34B	2.07B	6.38B

Cash Flow

Currency: KRW	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	3.68B	2.94B	3.29B	3.93B	3.78B
Investing Cash Flow	-	-1.22B	-4.77B	-13.31B	-
Financing Cash Flow	-	-410.06M	175.19M	12.45B	-
Capital Expenditure	200.89M	630.92M	271.37M	717.44M	12.88B
Free Cash Flow	3.48B	2.31B	3.02B	3.21B	-9.10B
FCF to OCF	94.54%	78.56%	91.76%	81.74%	-240.84%

Earnings

Report Date	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-
EPS Actual	160.10	112.65	69.27	162.43	276.09	300.48	216.77	181.34
Surprise	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap28.51B

Enterprise Value14.90B

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.87

Price / Book0.64

Revenue (TTM)32.90B

Gross Profit (TTM)9.19B

EBITDA6.36B

Profit Margin15.67%

Operating Margin12.91%

Return on Equity12.18%

Return on Assets6.20%

Shares Outstanding5.29M

Shares Float2.82M

Beta0.35

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%